FDA gives Fast Track Designation to tebentafusp by Anna Smith | Apr 4, 2019 | News | 0 The drug has already been granted orphan drug designation for melanoma by the FDA. Read More
GSK picks third target in Immunocore discovery deal by Selina McKee | Jul 3, 2017 | News | 0 GlaxoSmithKline has selected a third target in its collaboration with Oxford, UK-based Immunocore to discover multiple novel targets in cancer not addressable with antibody-based technologies. Read More